Overview
Regorafenib in third-line treatment of metastatic colorectal cancer(mCRC) significantly prolongs the survival of patients, and its advancement has a sensitizing effect on postline chemotherapy and thus improves the prognosis of patients. Therefore, the present study was designed to include patients who achieved stable disease/partial response(SD/PR) after 3 months of second-line therapy and advance regorafenib to investigate the role of advance regorafenib in prolonging progression-free survival, prolonging the efficacy of overall survival, safety, and quality of life in patients with mCRC compared with standard second-line and third-line therapy.
Eligibility
Inclusion Criteria:
- Patients with histologically or cytologically confirmed metastatic colorectal cancer who have measurable metastatic disease according to the Resolute Efficacy Criteria for Solid Tumors (RECIST) version 1.1.
- Received standard second-line therapy, achieved stable disease(SD) and above by recist1.1 tumor assessment and maintained for 3 months.
- Eastern Oncology Collaborative Group(ECOG) physical status of 0 or 1 at trial entry and life expectancy ≥ 3 months.
- No bone marrow suppression and normal heart, lung, liver and kidney function.
- Voluntary participation in research.
Exclusion Criteria:
- Concurrent primary tumors of other types.
- MSI-H/dMMR type mCRC patients.
- Heart, liver, kidney, bone marrow insufficiency or mental abnormalities.
- Intolerant to treatment methods
- Concurrent participants in other clinical trials.
- Pregnant or lactating women.
- Patients deemed unsuitable for study participation by the remaining investigators.